Larkspur Health Acquisition Corp. (LSPR)

NASDAQ: LSPR · IEX Real-Time Price · USD
10.50
+0.30 (2.94%)
At close: Dec 5, 2022 9:38 AM
10.21
-0.29 (-2.76%)
After-hours: Dec 5, 2022 4:00 PM EST
2.94%
Market Cap 102.30M
Revenue (ttm) n/a
Net Income (ttm) -1.07M
Shares Out 10.03M
EPS (ttm) -0.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 20,011
Open 10.02
Previous Close 10.2
Day's Range 9.95 - 11.15
52-Week Range 9.8 - 10.61
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About LSPR

Larkspur Health Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on business in the biotechnology sector in the United States. The company was incorporated in 2021 and is based in Bridgewater, New Jersey. [Read more]

Industry Blank Check / SPAC
IPO Date Dec 21, 2021
Employees 2,021
Stock Exchange NASDAQ
Ticker Symbol LSPR
Full Company Profile

News

ZyVersa Therapeutics' CEO, Stephen C. Glover, and CCO, Karen A.

Annual Inflammasome Summit unites world renowned experts in inflammasome-targeted drug development and academia to share information and address knowledge gaps in this rapidly evolving field ZyVersa is ...

1 week ago - PRNewsWire

SEC Declares Form S-4 Registration Statement "Effective" for Proposed Business Combination of Larkspur Health Acquisi...

Special meeting of Larkspur stockholders scheduled for December 8, 2022, to vote on the proposed business combination of Larkspur with ZyVersa ZyVersa is a clinical stage biopharmaceutical company with ...

2 weeks ago - PRNewsWire

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is Invited Speaker at BioFlorida 2022 Annual Conference

Mr. Glover will be joining four other life science executives in a General Session titled, CEO Panel: Learn from the experts ZyVersa is a clinical stage biopharmaceutical company with two licensed propr...

1 month ago - PRNewsWire

ZyVersa Therapeutics and Larkspur Health Acquisition Corp. Announce Business Combination, Interim Financing and PIPE ...

Aggregate committed financing in support of the business combination now at $10.0 million ZyVersa and Larkspur entered into a definitive business combination agreement on July 20, 2022 ZyVersa is a clin...

2 months ago - PRNewsWire

Data Published in Frontiers in Molecular Neuroscience Demonstrate That ZyVersa's Inflammasome ASC Inhibitor, IC 100, ...

Age-related chronic inflammation induced by activation of NLRP1 inflammasomes is implicated in development and progression of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases IC 1...

3 months ago - PRNewsWire

ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Resea...

IC 100, a novel monoclonal antibody inflammasome ASC inhibitor, targets multiple types of inflammasomes to block initiation and perpetuation of damaging chronic inflammation IC 100 has broad tissue dist...

4 months ago - PRNewsWire